Clinical investigation of iris-claw phakic intraocular lens implantation for high myopia

Abstract

To investigate the efficacy and safety of an iris-claw phakic intraocular lens (ICPIOL) implantation for high myopia. A consecutive group of 25 eyes in 13 patients with -7.88 to -22.88 diopters (D) of myopia was implanted with the Verisyse ICPIOL (AMO), and was examined preoperatively and 1, 7 days, 1, 3, 6, and 12 months postoperatively. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), manifest refraction, intraocular pressure, and complications were evaluated. The implantation was successful in all of 25 eyes. Compared with preoperative data, UCVA, BCVA, and spherical equivalent (SE) were improved significantly. At 12-month postoperatively, UCVA was 0.5 or better in all eyes, in which the UCVA in 71.43% eyes was 0.8 or higher; No loss of BCVA was found, 2 lines of BCVA improvement was obtained in 95.24% of patients with ICPIOL, and 1 line BCVA improvement was seen in 4.76% of patients; the power of refraction in all eyes implanted with ICPIOL was stabilized within the variation of +/- 0.50D (71.43%), and +/- 1.00D (85.71%). The corneal endothelial loss was insignificant. No severe complications occurred. At short-term follow-up, the implantation of the ICPIOL proved to be safe and effective for the correction of myopia in phakic eyes. However, longer follow-up with larger numbers of patients is necessary to evaluate long-term complications.